CDNA CareDx, Inc.
FY2025 10-K
CareDx, Inc. (CDNA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Specialized molecular diagnostic testing and digital pharmacy solutions for transplant patients
- • Expanded patient and digital solutions revenue by 31%, driven by pharmacy sales growth and wider Ottr software deployment
Management Discussion & Analysis
- • Revenue recognition includes testing services, product sales, patient and digital solutions; testing revenue reduced by $3.5M refund reserve in 2025
- • No specific total revenue or YoY change disclosed in the MD&A section provided
Risk Factors
- • MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025
- • Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision
Get deeper insights on CareDx, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.